Can donor immune cells help fight pancreatic cancer after surgery?
NCT ID NCT06730009
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding donor natural killer (NK) cells to standard chemotherapy can help prevent cancer from coming back after surgery for pancreatic or bile duct cancer. About 42 adults who had their tumor removed will receive either chemotherapy alone or chemotherapy plus NK cell infusions. The trial first finds the safest dose of NK cells, then compares how long people stay cancer-free in each group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
donor natural killer (NK) cells combined with chemotherapy (S-1, leucovorin, oxaliplatin, gemcitabine)
What this could lead to
If it works, this could point toward a way to delay or prevent cancer recurrence after surgery for pancreatic or bile duct cancer.
What could go wrong
This is an early, small trial (42 people) testing a new cell therapy for the first time in humans. The added benefit over chemotherapy alone is unproven, and there may be unknown side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cheng Kung University Hospital
RECRUITINGTainan, 138, Taiwan
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact